Actavis plans ‘major’ sales expansion in Latin America
pharmafile | October 6, 2011 | News story | Sales and Marketing | Actavis, emerging markets, generics
Swiss company Actavis has launched a new business unit to target the fast-growing Latin American generics market.
Mirroring the branded pharma industry’s interest in the region, generics company Actavis names Brazil as one of the key markets it aims to target.
Sales of generic drugs in Latin America grew by 14% between 2009 and 2010, compared to 4.4% worldwide, to reach a total of $53.4 billion last year, according to IMS Health.
The company said its new unit, which will operate as part of Actavis’ US business, heralded a “major sales expansion” into the region.
It will be led by Ricardo Quirch, who joins Actavis from Novartis’ generics division Sandoz, where he most recently led cross-divisional Asia-Pacific sourcing for the company.
“The decisions we are making now will have long-term benefits for health consumers in these countries,” said Quirch. “We began with two products that we acquired several years ago and are now reviewing more than 20 products to potentially add to our portfolio, and in the process of receiving regulatory approval to begin marketing others.”
The world’s fourth largest generic pharmaceutical company, Actavis is planning another major expansion of its operations to boost its presence in Japan.
Dominic Tyer
Related Content

Leading pharmaceutical companies sued in US for conspiring to drive up generics prices
26 pharmaceutical companies are being sued by most US states for allegedly conspiring to reduce …

Trump signs deal with generics company Phlow Corp to help shift drug manufacturing to the US
The Trump administration will sign a $354 million deal with the generics company Phlow Corp …

How the intended role of generic medicines is being undermined in America
The introduction of a generic medicine should, in theory, incentivise companies to lower the price of …






